Arcadia Biosciences (NASDAQ:RKDA) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the basic materials company’s stock.

Arcadia Biosciences Price Performance

Shares of NASDAQ RKDA opened at $3.32 on Friday. The firm’s 50-day moving average is $4.53 and its two-hundred day moving average is $4.11. The company has a market capitalization of $4.54 million, a PE ratio of -0.78 and a beta of 0.86. Arcadia Biosciences has a 12-month low of $1.85 and a 12-month high of $10.31.

Institutional Investors Weigh In On Arcadia Biosciences

A hedge fund recently bought a new stake in Arcadia Biosciences stock. Geode Capital Management LLC acquired a new stake in shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned about 0.90% of Arcadia Biosciences as of its most recent SEC filing. 17.73% of the stock is owned by institutional investors and hedge funds.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.